scholarly journals Patient-Specific Dosimetry and Radiobiological Modeling of Targeted Radionuclide Therapy Grant - final report

2007 ◽  
Author(s):  
Ph D George Sgouros
Keyword(s):  
Radionuclide Therapy ◽  
Patient Specific ◽  
Final Report ◽  
Targeted Radionuclide Therapy

SU-E-T-256: Optimizing the Combination of Targeted Radionuclide Therapy Agents Using a Multi-Scale Patient-Specific Monte Carlo Dosimetry Platform

2014 ◽  
Vol 41 (6Part15) ◽  
pp. 282-282
Author(s):  
A Besemer ◽  
B Titz ◽  
J Grudzinski ◽  
J Weichert ◽  
L Hall ◽  
...  
Keyword(s):  
Monte Carlo ◽  
Radionuclide Therapy ◽  
Patient Specific ◽  
Targeted Radionuclide Therapy ◽  
Multi Scale

scholarly journals Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404

2017 ◽  
Vol 62 (15) ◽  
pp. 6008-6025 ◽  
Author(s):  
Abigail E Besemer ◽  
Benjamin Titz ◽  
Joseph J Grudzinski ◽  
Jamey P Weichert ◽  
John S Kuo ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Tumor Volume ◽  
Patient Specific ◽  
Targeted Radionuclide Therapy ◽  
Volume Segmentation

scholarly journals Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma

2014 ◽  
Vol 17 (2) ◽  
pp. 284-294 ◽  
Author(s):  
Shih-ying Huang ◽  
Wesley E. Bolch ◽  
Choonsik Lee ◽  
Henry F. Van Brocklin ◽  
Miguel H. Pampaloni ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Ct Imaging ◽  
Patient Specific ◽  
Targeted Radionuclide Therapy ◽  
Dynamic Pet ◽  
Pet Ct ◽  
131I Mibg

Sci-Thurs AM: YIS-05: Accuracy of Patient-Specific Dosimetry for Clinical Use in Targeted Radionuclide Therapy

2009 ◽  
Vol 36 (9Part3) ◽  
pp. 4315-4316
Author(s):  
J Grimes ◽  
S Shcherbinin ◽  
A Celler ◽  
B Birkenfeld ◽  
MH Listewnik ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Patient Specific ◽  
Clinical Use ◽  
Targeted Radionuclide Therapy

Organs dosimetry in targeted radionuclide therapy

2021 ◽  
pp. 109668
Author(s):  
Meshari Alnaaimi ◽  
Abdelmoneim Sulieman ◽  
Mohammed Alkhorayef ◽  
Hasan Salah ◽  
Musa Alduaij ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy

scholarly journals Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma

2021 ◽  
Vol 14 (7) ◽  
pp. 626
Author(s):  
Julie Bolcaen ◽  
Shankari Nair ◽  
Cathryn H. S. Driver ◽  
Tebatso M. G. Boshomane ◽  
Thomas Ebenhan ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Tyrosine Kinases ◽  
Radionuclide Therapy ◽  
Kinase Inhibitors ◽  
Nuclear Imaging ◽  
Therapy Resistance ◽  
Targeted Radionuclide Therapy ◽  
Therapy Strategy ◽  
Dismal Prognosis

Glioblastoma (GB) remains the most fatal brain tumor characterized by a high infiltration rate and treatment resistance. Overexpression and/or mutation of receptor tyrosine kinases is common in GB, which subsequently leads to the activation of many downstream pathways that have a critical impact on tumor progression and therapy resistance. Therefore, receptor tyrosine kinase inhibitors (RTKIs) have been investigated to improve the dismal prognosis of GB in an effort to evolve into a personalized targeted therapy strategy with a better treatment outcome. Numerous RTKIs have been approved in the clinic and several radiopharmaceuticals are part of (pre)clinical trials as a non-invasive method to identify patients who could benefit from RTKI. The latter opens up the scope for theranostic applications. In this review, the present status of RTKIs for the treatment, nuclear imaging and targeted radionuclide therapy of GB is presented. The focus will be on seven tyrosine kinase receptors, based on their central role in GB: EGFR, VEGFR, MET, PDGFR, FGFR, Eph receptor and IGF1R. Finally, by way of analyzing structural and physiological characteristics of the TKIs with promising clinical trial results, four small molecule RTKIs were selected based on their potential to become new therapeutic GB radiopharmaceuticals.

scholarly journals Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 599
Author(s):  
Stephen Ahenkorah ◽  
Irwin Cassells ◽  
Christophe M. Deroose ◽  
Thomas Cardinaels ◽  
Andrew R. Burgoyne ◽  
...  
Keyword(s):  
Cancer Treatment ◽  
Radionuclide Therapy ◽  
Chemical Properties ◽  
High Energy ◽  
Magic Bullet ◽  
Targeted Radionuclide Therapy ◽  
Energy Photon ◽  
Normal Tissues ◽  
Preclinical And Clinical Studies ◽  
Alpha Therapy

In contrast to external high energy photon or proton therapy, targeted radionuclide therapy (TRNT) is a systemic cancer treatment allowing targeted irradiation of a primary tumor and all its metastases, resulting in less collateral damage to normal tissues. The α-emitting radionuclide bismuth-213 (213Bi) has interesting properties and can be considered as a magic bullet for TRNT. The benefits and drawbacks of targeted alpha therapy with 213Bi are discussed in this review, covering the entire chain from radionuclide production to bedside. First, the radionuclide properties and production of 225Ac and its daughter 213Bi are discussed, followed by the fundamental chemical properties of bismuth. Next, an overview of available acyclic and macrocyclic bifunctional chelators for bismuth and general considerations for designing a 213Bi-radiopharmaceutical are provided. Finally, we provide an overview of preclinical and clinical studies involving 213Bi-radiopharmaceuticals, as well as the future perspectives of this promising cancer treatment option.

Sign in / Sign up

Export Citation Format

Share Document